How Do You Build a Biotech’s Equity Research Coverage? (And Is There Such a Thing as Too Much Coverage?) Having an equity analyst take up coverage of your biotech (including their rationale, a recommendation and price target) costs money – either directly or indirectly. This is because equity analysts can be paid $1+ million a year, including bonus, depending on their prestige and the bank they work for (an analyst friend of mine gave me a sliding scale of $500k-$5M). In other words, they are not cheap. Read more about it on our blog.
